

WHAT IS CLAIMED IS:

1. A pharmaceutical composition for administration to a subject mammal exhibiting a diurnal cycle of plasma aldosterone concentration having an acrophase, the composition comprising a therapeutically effective amount of a delayed-release formulation of an aldosterone antagonist drug which, when orally administered about 6 to about 12 hours prior to the acrophase, provides a profile of plasma drug concentration corresponding substantially to the diurnal cycle of plasma aldosterone concentration.
2. The composition of Claim 1 wherein the profile of plasma drug concentration corresponds to the diurnal cycle of plasma aldosterone concentration substantially as depicted in Fig. 1.
3. A pharmaceutical composition comprising a delayed-release formulation of an aldosterone antagonist drug in a therapeutically effective amount, the composition exhibiting a release profile, as determined by a suitable test, in which:
  - (a) zero to about 20% by weight of the drug is released from the formulation at about 4 hours after initiation of the test; and
  - (b) about 50% to 100% by weight of the drug is released from the formulation within a time period of about 3 hours beginning at a time about 4 to about 12 hours after initiation of the test.
4. The composition of Claim 3 wherein the test is conducted according to U.S. Pharmacopeia 24, Test No. 711, using apparatus 2 at 50 rpm, with an aqueous dissolution medium containing 1% sodium dodecyl sulfate at 37°C, and wherein release is measured by dissolution of the drug in the medium.
5. The composition of Claim 3 wherein zero to about 10% by weight of the drug is released from the formulation at about 4 hours after initiation of the test.
6. The composition of Claim 3 wherein zero to about 20% by weight of the drug is released from the formulation at about 6 hours after initiation of the test.
7. The composition of Claim 3 wherein zero to about 10% by weight of the drug is released from the formulation at about 6 hours after initiation of the test.

8. The composition of Claim 3 wherein about 70% to 100% by weight of the drug is released from the formulation within said time period of about 3 hours.
9. The composition of Claim 1 that further comprises a second formulation comprising a therapeutically effective amount of a second antihypertensive agent.
10. The composition of Claim 9 wherein said second antihypertensive agent is selected from a diuretic, a sympatholytic agent, an ACE inhibitor, a vasopeptidase, a calcium channel blocker, a direct vasodilator, a renin inhibitor, and an angiotensin II antagonist.
11. The composition of Claim 9 wherein the second formulation containing the second antihypertensive agent exhibits a release profile that is different from the release profile exhibited by the delayed-release formulation containing the aldosterone antagonist.
12. The composition of Claim 11 wherein the second formulation is an immediate-release formulation.
13. The composition of Claim 11 wherein the second formulation is an extended-release formulation.
14. The composition of Claim 1 wherein the aldosterone antagonist is eplerenone.
15. The composition of Claim 1 that is in the form of an enteric coated tablet.
16. The composition of Claim 15 wherein the tablet comprises a core comprising an immediate-release formulation of the aldosterone antagonist substantially enclosed within an enteric coating.
17. The composition of Claim 1 that is in the form of a capsule containing enteric coated pellets.
18. The composition of Claim 17 wherein the pellets each comprise a core comprising an immediate-release formulation of the aldosterone antagonist substantially enclosed within an enteric coating.
19. A method of treating a mammal exhibiting (a) circadian rhythm in aldosterone secretion having an acrophase and (b) an aldosterone-mediated disease or

disorder, the method comprising orally administering to the mammal a composition of any of Claims 1-18 about 6 to about 12 hours prior to the acrophase.

20. The method of Claim 19 wherein the mammal is a human.
- 5 21. The method of Claim 20 wherein the disease or disorder is elevated blood pressure.
22. The method of Claim 20 wherein the acrophase occurs at the end of a sleep period and the composition is orally administered prior to the sleep period.

50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100